Posted on 06/03/2012 12:12:44 AM PDT by LibWhacker
A new drug for advanced prostate cancer patients has proved so effective that researchers stopped the clinical trial early to give all patients a chance to receive the life-extending medication, according to a UCSF-led study released Saturday.
The hormone treatment, Johnson & Johnson's Zytiga, when added to a standard steroid therapy doubled the time it takes for the disease to progress in patients treated with the standard therapy alone, said the lead researcher, Dr. Charles Ryan, associate professor of clinical medicine at the UCSF Helen Diller Family Comprehensive Cancer Center.
(Excerpt) Read more at sfgate.com ...
THAT trial has stopped due to efficacy. If you read the article, the drug was approved last year. This study looked at the use of zytiga in conjunction with a steroid therapy for men with metastasized prostate cancer who haven’t had chemo treatment.
The combination proved so successful stopping the trial was the ethical thing to do. You don’t watch people die just to gather a bit more data. There will be other trials, designed differently, to make the case for this treatment.
Also, J&J couldn’t stop that trial without consulting the FDA. There was no “cherry picking”. Johnson & Johnson wouldn’t risk billions of dollars on trying to trick the FDA that their drug works.
“Relax. It will still be 15 years before its on the shelf.”
Seriously, did ANYONE actually read the article? Sheesh!
And what I gather from your comments about evil “Big Pharma” I see you make similar judgments about things equally uninformed.
What do you call Kyle’s Dad? Flipper!
To further the analogy:
When all five decide to pay by Check, that’s the Gov’t getting involved.
You know, if you say things like “You dont watch people die just to gather a bit more data,” you’ll never be a Czar in the current administration.
Just sayin’.
ping
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.